Insider Selling: CG Oncology (NASDAQ:CGON) Director Sells 1,000 Shares of Stock

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 1,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $54.50, for a total value of $54,500.00. Following the transaction, the director owned 1,000 shares of the company’s stock, valued at $54,500. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

CG Oncology Price Performance

Shares of CG Oncology stock traded down $2.37 during trading on Friday, hitting $53.72. 954,021 shares of the company were exchanged, compared to its average volume of 1,194,295. The firm has a market capitalization of $4.74 billion, a P/E ratio of -23.06 and a beta of 0.31. CG Oncology, Inc. has a 1-year low of $23.65 and a 1-year high of $75.50. The firm’s fifty day moving average price is $66.22 and its 200 day moving average price is $56.04.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. As a group, equities research analysts anticipate that CG Oncology, Inc. will post -2.89 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on CGON shares. Wall Street Zen lowered CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. JPMorgan Chase & Co. boosted their target price on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research report on Monday, April 20th. Wolfe Research started coverage on CG Oncology in a research report on Tuesday, May 19th. They set a “peer perform” rating for the company. Finally, Truist Financial reiterated a “buy” rating and set a $82.00 price objective (up from $77.00) on shares of CG Oncology in a report on Thursday, May 14th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, CG Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $81.73.

Hedge Funds Weigh In On CG Oncology

Institutional investors have recently modified their holdings of the business. Candriam S.C.A. lifted its holdings in shares of CG Oncology by 35.9% during the 3rd quarter. Candriam S.C.A. now owns 1,037,892 shares of the company’s stock valued at $41,806,000 after purchasing an additional 274,312 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in CG Oncology by 321.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 227,879 shares of the company’s stock valued at $9,179,000 after acquiring an additional 173,785 shares in the last quarter. Vanguard Group Inc. lifted its stake in CG Oncology by 11.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after acquiring an additional 670,770 shares in the last quarter. Mangrove Partners IM LLC lifted its stake in CG Oncology by 21.0% in the 3rd quarter. Mangrove Partners IM LLC now owns 671,692 shares of the company’s stock valued at $27,056,000 after acquiring an additional 116,575 shares in the last quarter. Finally, Sivik Global Healthcare LLC bought a new stake in CG Oncology in the 4th quarter valued at approximately $1,453,000. Institutional investors own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.